PAPILLON Trial Insights: ESMO 2023

EP: 1.CheckMate 77T: Perioperative Immunotherapy in Resectable NSCLC

EP: 2.Evolving NSCLC Landscape: Comparing Recent Updates in Neoadjuvant and Perioperative Immunotherapy

EP: 3.Updates in ALK+ NSCLC: ALINA Trial at ESMO 2023

EP: 4.Lessons from LIBRETTO-431 Trial in RET+ NSCLC

Now Viewing

EP: 5.PAPILLON Trial Insights: ESMO 2023

EP: 6.Innovations Needed and Future Directions in Treatment of NSCLC

This is a video synopsis/summary of a Post Conference Perspectives involving Patrick Forde, MBBCh.

Forde discusses results from the PAPILLON trial (NCT04538664) of amivantamab, a bispecific antibody targeting EGFR and MET in EGFR exon 20 insertion–mutated non–small cell lung cancer (NSCLC). EGFR exon 20 insertions occur in about 2% 3% of NSCLC cases, predominantly nonsquamous histology. Amivantamab is approved in previously treated EGFR exon 20 NSCLC.

The PAPILLON trial compared amivantamab plus chemotherapy with chemotherapy alone in untreated advanced EGFR exon 20 NSCLC. Amivantamab plus chemotherapy significantly improved progression-free survival with an HR of 0.395 vs chemotherapy alone. Objective response rate increased from 47% with chemotherapy to 73% with amivantamab plus chemotherapy. There was also an early overall survival trend favoring amivantamab.

Patrick Forde, MBBCh summarized clinical practice impact of the PAPILLON data, “overall, I think this does move the needle for our patients with advanced EGFR Exon 20 mutated lung cancer, in that I think we will now begin to use chemotherapy plus amivantamab upfront. There are some side effects from amivantamab, which we need to be aware of, in that there can be infusion-related reactions, which are usually self-limiting, but definitely occur on the first few treatments. The treatments are relatively frequent in that they're weekly initially.”

Video synopsis is AI-generated and reviewed by AJMC^® editorial staff.